ArticleRSC advances2023
Macrophage-targeted nanoparticles mediate synergistic photodynamic therapy and immunotherapy of tuberculosis.
Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Actively Targeted Nanoparticles for Enhanced Diagnosis, Treatment, and Vaccination of Tuberculosis: A Systematic Review.International journal of nanomedicine · 2025Pooled it
- Extracorporeal near-infrared-activated antimicrobial photodynamic therapy for pneumonia using an ICG-polymer formulation.Biophotonics discovery · 2026Article
- Advancing Tuberculosis Chemotherapy: Targeted Nanomedicines for the Mycobacterium TB Granuloma.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Immunotherapy for tuberculosis: current strategies and future directions.Military Medical Research · 2025Review
- In vivo antimicrobial activity of engineered mesoporous silica nanoparticles targeting intracellular mycobacteria.Nature communications · 2025Article
- Exploring the application of herbal photosensitizers in antimicrobial photodynamic therapy against3 Biotech · 2025Review
- Photothermal and host immune activated therapy of cutaneous tuberculosis using macrophage targeted mesoporous polydopamine nanoparticles.Materials today. Bio · 2024Article
- Enhancing TB Vaccine Efficacy: Current Progress on Vaccines, Adjuvants and Immunization Strategies.Vaccines · 2023Review
- Metal-Organic Framework-Based Nanomedicines for the Treatment of Intracellular Bacterial Infections.Pharmaceutics · 2023Review
- Nanosized Drug Delivery Systems to Fight Tuberculosis.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) is an infectious disease caused by
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.